Roche hemophilia drug lowers costs despite high price: ICER

(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

https://www.reuters.com/article/us-roche-hemophilia-icer/roche-hemophilia-drug-lowers-costs-despite-high-price-icer-idUSKBN1FG00O